tbuckley/cabot-search huggingface dataset:
Abstract P164: Understanding The Health Of Mothers Of A Child With Congenital Heart Disease Utilizing Electronic Health Record Data
Authors: Rebecca K Delaney, Sergiusz Wesolowski, Martin Tristani-Firouzi, Angela Fagerlin, Nelangi M Pinto, Gordon Lemmon, Alex Henrie, Mark Yandell
Journal: Circulation (2021)

Introduction: With improved survival of children with congenital heart disease (CHD), more parents are managing medical care for their child into adulthood, which can negatively affect parental health. The prevalence of mental and physical health conditions in affected mothers are not well quantified. Hypothesis: Mothers of a child with CHD (excluding mild CHD) have increased odds of being diagnosed with mental and physical health conditions compared to mothers of a child without CHD. Methods: A retrospective study with linked maternal-child EHR data was conducted. Kernel density plots, two sample Kolmogorov Smirnov test, and Bayesian networks were used for analyses. Results: A total of 3,480 mothers of a child with CHD and 252,206 mothers without a child with CHD were identified. Densities significantly differed between groups for most diagnoses and often occurred earlier for mothers with a child with CHD. Mothers of child with CHD (≤40 years) had increased odds of having a mental or physical health diagnosis (Figure &amp; Table). Conclusion: Understanding how to support mothers of a child with CHD and improve engagement in preventive health behaviors is critical.
130TiP SOLTI-1303 PATRICIA 2 randomized phase II trial of palbociclib plus trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype
Authors: E.M. Ciruelos, A.A. Garcia, J. Cortés, S. Pernas Simon, E. Garate, M. Melé, Á. Montaño, N. Martinez-Jañez, M. Oliveira, J. de la Haba-Rodríguez, E. Vega, A. Perello Martorell, B. Bermejo De Las Heras, B. Cantos Sanchez De Ibarguen, E. Martínez, E. Vila Navarro, T. Pascual, X. González-Farré, P. Villagrasa, A. Prat
Journal: Annals of Oncology (2021)
HIV/AIDS患者における眼症状:病院ベースの遡及的研究【JST・京大機械翻訳】
Authors: Li Wangting, Wang Xiaoli, Zhao Lanqin, Lin Duoru, Liu Zhenzhen, Wu Xiaohang, Wang Jinghui, Zhang Xiayin, Yang Yahan, Wang Ruixin, Li Ruiyang, Huang Wenyong, Lin Haotian
Journal: The Lancet (2019)
The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape
Authors: Madelon M. E. de Jong, Zoltán Kellermayer, Natalie Papazian, Sabrin Tahri, Davine Hofste op Bruinink, Remco Hoogenboezem, Mathijs A. Sanders, Pieter C. van de Woestijne, P. Koen Bos, Cyrus Khandanpour, Jessica Vermeulen, Philippe Moreau, Mark van Duin, Annemiek Broijl, Pieter Sonneveld, Tom Cupedo
Journal: Nature Immunology (2021)
LBA1 20-year benefit of endocrine therapy in premenopausal breast cancer patients by the 70-gene risk signature
Authors: A. Johansson, H. Dar, L. Van ‘T Veer, G. Perez-Tenorio, A. Nordenskjöld, C. Yau, C. Benz, L. Esserman, O. Stål, B. Nordenskjöld, T. Fornander, L. Lindström
Journal: Annals of Oncology (2021)
Abstract 15704: Morbidity and Mortality After Anatomic Repair of Congenitally Corrected Transposition of the Great Arteries: Understanding Risks for Patient and Family Counseling
Authors: Kimberly J Watkins, Rebecca R Hartog, Megan Wilde, Tiffany R Lim, Andrew Rodenbarger, Ray Lowery, Sunkyung Yu, Katherine Afton, Caren S Goldberg, Richard G Ohye, Michael G Gaies
Journal: Circulation (2020)

Introduction: Anatomic repair of congenitally corrected transposition of the great arteries (ccTGA) generally poses short-term risk for presumed long-term functional benefit by restoring the left ventricle to the systemic circulation. Understanding early and late surgical outcomes is crucial for counseling patients and families. Methods: All patients with anatomic repair at a single institution from 1993-2018 were included. Follow-up data was obtained by contact with patients’ primary cardiologists. The primary outcome was long-term survival and the secondary outcome was freedom from reintervention. Univariate Cox proportional hazard model was used to identify risk factors for mortality. In-hospital mortality and morbidity were compared between the most recent (2010-2018) and past surgical eras. Results: Anatomic repair was performed in 118 patients: 64 Senning/arterial switch operations (ASO) and 54 Senning/Rastelli operations. Survival was 85%, 82%, and 70% at 1, 10, and 20 years after repair, respectively, and was significantly lower in the Senning/Rastelli group compared to Senning/ASO (Hazard ratio 3.0, p=0.01; Figure 1). Preoperative factors associated with mortality were heterotaxy syndrome (p=0.03) and right ventricular systolic dysfunction (p=0.01). During a median follow up of 9.4 years, 47 of 98 patients (48%) required surgical or catheter-based reintervention; median freedom from reintervention was 11.7 years. For the most recent era, 30 of 32 patients (94%) with Senning/ASO and 19 of 22 patients (86%) with Senning/Rastelli operations survived to hospital discharge. In-hospital morbidity was similar between eras (30% in 1993-2009 and 28% in 2010-2018, p=0.82). Conclusions: Short- and long-term outcomes are favorable following Senning/ASO. Mortality following Senning/Rastelli operations remains high, highlighting the need for careful patient selection and family counseling.
(Chemo)Radiotherapy–Immunotherapy Combinations: Time to Get Tailored?
Authors: Michele Mondini, Eric Deutsch
Journal: Clinical Cancer Research (2021)

Abstract Chemoradiotherapy is considered an immunogenic anticancer treatment. Data obtained during the course of chemoradiotherapy treatment of patients with cervical cancer show heterogeneous changes in the tumor immune landscape, highlighting the need for patient selection to rationally design successful combined immunotherapies. Blood-based biomarkers could be valuable to perform such stratification. See related article by Chen et al., p. 3990
Correspondence on ‘Warfarin use and risk of knee and hip replacements’
Authors: Chao Cheng, Fangjie Zhang
Journal: Annals of the Rheumatic Diseases (2021)

Correspondence on 'Warfarin use and risk of knee and hip replacements'We read with deep interest the article by Priyanka Ballal et al, 1 who investigated the risks of joint replacement associated with warfarin in comparison with direct oral anticoagulant (DOAC) usage.The authors concluded that warfarin, a vitamin K antagonist, was associated with a greater risk of KR and HR than DOACs.However, we noticed that the percentages of patients receiving non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol were 39.3% and 67.8%, respectively, in the knee replacement/hip replacement (KR/HR) group (n=857) and 37.2% and 39.1%, respectively, in the control group (n=3428).Thus, the total analgesic usage was significantly higher in the KR/HR group, indicating more severe pain in the patients in this group.The principal clinical indication for knee and hip replacement is end-stage arthritis, or with persistent severe joint pain 2 3 ; the joint pain is generally more severe in end-stage arthritis, and the degree of joint pain can reflect the severity of arthritis.However, the authors did not state the order of administration of analgesics and warfarin.Did warfarin increase the use of analgesics?Or were warfarin and analgesics started at the same time?Or was the analgesic administered before warfarin?Furthermore, the paracetamol usage rate differed in the two groups (67.8% vs 39.1%).Paracetamol has been confirmed to potentiate the anticoagulant response produced by warfarin, 4 and this potentiation effect is likely to result from the ability of N-acetyl-para-benzoquinoneimine, paracetamol's toxic metabolite, to inhibit the enzymes of the vitamin K cycle. 5Warfarin's anticoagulant effects also occur through inhibition of vitamin K functioning, which leads to inadequate functioning of Gla proteins and might be associated with the progression of osteoarthritis.Taken together, these aspects indicate the need to further consider the interaction between paracetamol and warfarin and the influence of paracetamol on the effects of warfarin on osteoarthritis progression.We respect the significant contributions of the authors and look forward to the follow-up results of this study.
제 7 차 춘계학술대회 초록집 : 특강 ; 간세포암종의 병리학적 분류와 딜렘마 - 바른 분류를 도출하기 위한 병리형태학적 소견의 재해석을 위하여 -
Authors: 김용일
Journal: Clinical and Molecular Hepatology (2001)
Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia
Authors: Nitin Jain, Abhishek Maiti, Farhad Ravandi, Marina Konopleva, Naval Daver, Tapan Kadia, Naveen Pemmaraju, Nicholas Short, Partow Kebriaei, Jing Ning, Jorge Cortes, Elias Jabbour, Hagop Kantarjian
Journal: American Journal of Hematology (2021)

Abstract Relapsed/refractory (R/R) Philadelphia chromosome positive acute lymphoblastic leukemia (Ph + ALL) and lymphoid blast phase of chronic myeloid leukemia (LBP‐CML) have poor outcomes. We designed a phase 1/2 study combining inotuzumab ozogamicin with bosutinib for this patient population. Patients with T315I mutation were excluded. Bosutinib was administered daily at three dose levels (300 mg/d, 400 mg/d, 500 mg/d) in a 3 + 3 design. Inotuzumab ozogamicin was dosed weekly during cycle one, and once every 4 weeks subsequently for a total of six cycles. The primary objective was to determine the safety and the maximum tolerated dose (MTD) of bosutinib in combination with inotuzumab ozogamicin. Eighteen patients were enrolled (Ph‐positive ALL, n = 16; LBP‐CML, n = 2). The median age was 62 years (range, 19–74) and the median number of prior therapies was one (range, 1–5). Dose limiting toxicities included grade 3 skin rash and bosutinib 400 mg daily was determined as the MTD. The most frequent grade 3/4 treatment‐emergent adverse events were thrombocytopenia (60%) and neutropenia (38%). A complete response (CR) / CR with incomplete count recovery (CRi) was achieved in 15/18 (83%) patients; 11/18 (61%) patients achieved negative measurable residual disease by flow cytometry. Complete molecular response was noted in 10/18 (56%) patients. The 30‐day mortality was 0%. After a median follow‐up of 44 months, the median duration of response and overall survival were 7.7 months and 13.5 months, respectively. Six patients had a subsequent allogeneic stem cell transplant. No patient developed veno‐occlusive disease. Inotuzumab ozogamicin with bosutinib was well tolerated in R/R Ph‐positive ALL and LBP‐CML.
3O Spatial analysis of lymphocytes and fibroblasts identifies biological relevant patterns in estrogen receptor positive breast cancer
Authors: I. Nederlof, S. Hajizadeh, F. Sobhani, S.A. Raza, C. Desmedt, R.F. Salgado, M. Kok, Y. Yuan, H. Horlings
Journal: Annals of Oncology (2021)
Conducting Polymer‐Ionic Liquid Electrode Arrays for High‐Density Surface Electromyography
Authors: Santiago Velasco‐Bosom, Nuzli Karam, Alejandro Carnicer‐Lombarte, Johannes Gurke, Nerea Casado, Liliana C. Tomé, David Mecerreyes, George G. Malliaras
Journal: Advanced Healthcare Materials (2021)

Abstract Surface electromyography (EMG) is used as a medical diagnostic and to control prosthetic limbs. Electrode arrays that provide large‐area, high density recordings have the potential to yield significant improvements in both fronts, but the need remains largely unfulfilled. Here, digital fabrication techniques are used to make scalable electrode arrays that capture EMG signals with mm spatial resolution. Using electrodes made of poly(3,4‐ethylenedioxythiophene) polystyrene sulfonate (PEDOT:PSS) composites with the biocompatible ionic liquid (IL) cholinium lactate, the arrays enable high quality spatiotemporal recordings from the forearm of volunteers. These recordings allow to identify the motions of the index, little, and middle fingers, and to directly visualize the propagation of polarization/depolarization waves in the underlying muscles. This work paves the way for scalable fabrication of cutaneous electrophysiology arrays for personalized medicine and highly articulate prostheses.
Abstract P021: Association Of Resting Heart Rate With All-cause And Cardiovascular Mortality: Sprint
Authors: Steven J Mould, Elsayed Z Soliman, Yashashwi Pokharel, Elijah Beaty, Prashant Bhave, S P Whalen, Joseph Yeboah, Matthew J Singleton
Journal: Circulation (2021)

Introduction: Elevated resting heart rate (RHR) has been shown to be associated with both all-cause and cardiovascular mortality. Prior studies have provided conflicting estimates of the strength of each association. To explore the relationship between RHR and competing mortality risks, we sought to compare the association between RHR and cardiovascular and non-cardiovascular mortality among participants in the Systolic Blood Pressure Intervention Trial (SPRINT). Methods: Eligible SPRINT participants had baseline RHR, longitudinal follow-up, and were not using beta blockers or non-dihydropyridine calcium channel blockers. Mortality was classified by a treatment-blinded adjudication committee as cardiovascular if secondary to coronary heart disease, stroke, sudden cardiac death, or congestive heart failure. Multivariable Cox proportional hazards models were used to calculate the hazard ratios (HRs) and 95% confidence intervals (95% CI) for cardiovascular and non-cardiovascular mortality, separately, associated with a 10 beats per minute increase in RHR. Results: Among 5,571 eligible SPRINT participants (67.1 ± 9.4 years, 33.8% female, 63.8% white, mean RHR 70.4±11.8 beats per minute) over a median 3.8 years of follow-up, there were 56 cardiovascular deaths and 176 non-cardiovascular deaths. In models adjusted for age, sex, race, prior cardiovascular disease, smoking, systolic blood pressure, creatinine, total cholesterol, high-density lipoprotein cholesterol, and trial treatment assignment, higher RHR (per ten beat-per-minute increase) was associated with both cardiovascular (HR 1.17, 95% CI 1.02-1.35) and non-cardiovascular mortality (HR 1.27, 95% CI 1.13-1.43). Conclusions: Elevated RHR was associated with both cardiovascular and non-cardiovascular mortality, suggesting that RHR may serve as a marker of both global health rather and cardiovascular health. Higher RHR may reflect imbalance in autonomic tone and further studies are needed to explore the mechanisms of these associations.4
Abstract 15077: Serum-transthyretin: Does it Predict Ablation Outcome in Patients With Atrial Fibrillation?
Authors: Sanghamitra Mohanty, CHINTAN G TRIVEDI, Joseph Gallinghouse, Domenico G Della Rocca, Carola Gianni, Bryan MacDonald, Angel Mayedo, Faiz Baqai, Rong Bai, Mohamed Bassiouny, John Burkhardt, Rodney Horton, Amin Al-ahmad, Andrea Natale
Journal: Circulation (2020)

Background: Transthyretin (TTR), a transport protein produced by liver, is closely associated with amyloidosis. Tetramers of TTR circulating in blood can dissociate to monomers that misassemble into amyloid fibrils. Although amyloidosis is a frequent finding in aged atrial fibrillation (AF) patients, the relevance of serum-TTR in AF is unknown. Objective: We evaluated if post-ablation change in serum-TTR level has any prognostic association with long-term ablation outcome in AF patients. Methods: One-hundred-forty-five patients (age: 62.8 ± 6.2years, male 69%, non-paroxysmal AF 41%, BMI : 30.8 ± 6.3) were included in this prospective study. Patients with chronic inflammatory conditions or taking anti-inflammatory drugs were excluded. All patients received pulmonary vein isolation plus isolation of left atrial posterior wall and superior vena cava. In non-paroxysmal AF, non-PV triggers identified by isoproterenol challenge were ablated. Fasting blood samples were collected at baseline and 24-hours post-ablation. Samples were tested for TTR using an automated quantitative test. Results: Mean TTR concentration was 27.94±6.5 mg/dL at baseline and 26.33±9.2 mg/dL at 24-hour post ablation (p&lt;0.001). Of the 145 patients, post-ablation TTR remained unchanged or increased in 65 (44.8%) and decreased in 80 (55.2%) patients at 24-hour post-ablation. Mean decrease in the serum TTR in these 80 patients was 7.9± 4.38 mg/dL. At 3 years of follow-up, the recurrence rate was 28/80 (35%) in the group with decreased-serum TTR and 11/65 (17%) in the population with unchanged/increased TTR (p=0.01). Post-ablation decrease in TTR was found to be an independent predictor of recurrence (OR 2.64 (1.19-5.85), p=0.01). Conclusion: Our findings demonstrated significant association of higher recurrence rate with decreased serum-TTR tetramer level at 24-hour post-ablation.
Systematic monitoring for detection of atrial fibrillation in patients with acute ischaemic stroke (MonDAFIS): a randomised, open-label, multicentre study
Authors: Karl Georg Haeusler, Paulus Kirchhof, Claudia Kunze, Serdar Tütüncü, Cornelia Fiessler, Carolin Malsch, Manuel C Olma, Muhammad Jawad-Ul-Qamar, Michael Krämer, Rolf Wachter, Dominik Michalski, Andrea Kraft, Timolaos Rizos, Klaus Gröschel, Götz Thomalla, Darius G Nabavi, Joachim Röther, Ulrich Laufs, Roland Veltkamp, Peter U Heuschmann, Matthias Endres, Michael Bauerle, Michael Besselmann, T Büttner, Petra Dem, Jens Diekmann, Joanna Dietzel, Rainer Dziewas, Sven Ehrlich, Annette Evens, Georg Gahn, Albrecht Günther, Gerhard F Hamann, Andreas Hartmann, Karen Louise Harvey, Fedor Heidenreich, T Helberg, Carsten Hobohm, F Hoffmann, Olaf Hoffmann, Gerhard J Jungehulsing, Eva-Maria Kampschulte, Peter Kraft, Christos Krogias, Elke Leinisch, Matthias Maschke, Stefan Merkelbach, Johannes Muehler, Ludwig Niehaus, Gesa Nören, P Oschmann, Frederick Palm, Gabor C Petzold, Larissa Pfeiler, Waltraud Pfeilschifter, Marie Prince, Peter Ringleb, Michael Rosenkranz, Georg Royl, Renate B Schnabel, Johannes Schurig, A Steinbrecher, Robert Stingele, Christian Tanislav, Louise Tyler, Christian Urbanek
Journal: The Lancet Neurology (2021)
Impact of tumor VEGF expression level on radiotherapy response.
Authors: Christina M. Norris, Dietmar W. Siemann
Journal: Cancer Research (2006)

5313  Since angiogenesis is an important process in the growth and survival of tumors, the present studies were conducted to examine the role of tumor VEGF expression on tumor response to radiotherapy. Clonal cell lines of two tumor types, a human colon carcinoma (HT29) and a murine squamous cell carcinoma (SCCVII), were created via infection with a recombinant adeno-associated virus containing the gene for human VEGF. Three clones were then chosen for each tumor model: the first clone expressed VEGF at a level comparable to the parental (non-infected) cell line, the second expressed VEGF at an intermediate level (20 fold greater), and the third clone expressed VEGF at an approximate 60 fold greater concentration. The in vitro growth kinetics and the inherent radiation sensitivities of the clonal cell lines did not significantly differ from that of the parental cell line. However, in vivo, differences in growth rate and response to radiotherapy were observed. In the radiation studies, tumors derived from the various VEGF clones were irradiated with a 10 Gy dose of radiation when the tumors reached a size of ∼200 mm3. The time taken for each tumor to grow to 1000 mm3 was then determined and the growth delay calculated. The results showed that tumors from the highest expressing VEGF clonal cell line demonstrated an enhanced response to radiation (increased growth delay when compared to the parental cell line; 19 vs 10 days in the HT29 tumor model and 16 vs 2 days in the SCCVII tumor model). The results from this investigation therefore imply that a tumor’s angiogenic potential may play an important role in its response to radiation. One possible explanation for these results is that increased angiogenesis may result in improved tumor oxygenation. Indeed, preliminary data have shown that those tumors resulting from the highest expressing VEGF clonal cell lines have a two to three-fold increase in vascular density, as determined by CD31 staining. The level of hypoxia and the proliferation rate of the neoplastic cells in these tumor models are currently being investigated.
Abstract 15312: Racial Disparities in Trends in Mortality From Cardiac Arrests in the United States
Authors: Anas M Al Zubaidi, Graham Bevan, Mariam Rana, Abdul Rahman Al Armashi, Mustafa Alqaysi, Sadeer Al-Kindi
Journal: Circulation (2020)

Background: African Americans are at increased risk of fatal cardiac arrests, but population-based studies exploring contemporary epidemiology are not available. We sought to identify the trend in race-specific mortality from cardiac arrest in the United States. Methods: Using the multiple cause of death database, we identified all patients (Caucasians or African Americans) who died of cardiac arrest (International Classification of Diseases, 10th revision code I46.x listed as underlying cause of death) between 1999 and 2018. Age-adjusted mortality rates were standardized to the 2000 US census data, and stratified by age group (&lt;35 years, 35-64 years, and ≥ 65 years). Results: A total of 311,065 cardiac arrest deaths were identified, with an overall age-adjusted mortality of 53.6 per million (Caucasian: 49.1 per million, African American: 90.6 per million). Overall, age-adjusted mortality decreased from 80.1 per million persons (1999) to 44.3 per million persons (2012), followed by 8.8% increase to 48.2 (2018). Between 2012 and 2018, African Americans had higher rates of increase (10.9%) compared with Caucasians (6.9%). Largest disparities in relative changes between 2012 and 2018 occurred in patients younger than 35 years (African American: 35%, Caucasians -11%), and patients ≥ 65 years (African Americans: 8%, Caucasians 4%), figure. Conclusions: Although the mortality due to cardiac arrest has declined in the US between 1999 and 2012, a recent increase has been noted between 2012 and 2018, particularly among younger African Americans. Studies should focus on identifying causes of disparities and identifying methods to reduce the racial gap.
The Use of a BH3 Mimetic Toolkit Reveals a Switch of Myeloma Patients Dependency from BCL2 at Diagnosis to MCL1 at Relapse
Authors: Antoine Bonnet, Jessie Bourcier, Patricia Gomez-Bougie, Sophie Maïga, Benoit Tessoulin, Philippe Moreau, Steven Le Gouill, Catherine Pellat-Deceunynck, Cyrille Touzeau, Martine Amiot
Journal: Blood (2017)